Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1189
- Development stage
- Phase 2
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1189 is an investigational prophylactic vaccine developed by Moderna for the prevention of Epstein-Barr virus (EBV) infection and infectious mononucleosis. It consists of a lipid nanoparticle encapsulating four messenger RNAs encoding the EBV envelope glycoproteins gp42, gp220, gH, and gL. These proteins mediate viral entry into B-cells and epithelial cells—the primary targets of EBV infection—by being expressed in their native membrane-bound form to elicit an immune response. The vaccine is designed to stimulate the immune system against EBV and prevent associated diseases such as infectious mononucleosis. As of March 2024, mRNA-1189 has completed Phase 1 trials and is advancing toward pivotal Phase 3 studies[1][3][5][8].
- Other names
- lipid nanoparticle-encapsulated EBV mRNA vaccineEpstein Barr virus vaccine - Moderna Therapeutics
02
Targets
gp220 (Epstein-Barr virus glycoprotein gp220)GH (Growth hormone)gp42 (Epstein-Barr virus glycoprotein 42)gL (Epstein-Barr virus glycoprotein L)
Beyond the preview
Go deeper on mRNA-1189.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1189.